State Street Holds 6.1% Of ADMA — Its Position Is Passive

The position covered 13,675,348 shares as of September 30, against the backdrop of ADMA's recent rally.

Share
State Street Holds 6.1% Of ADMA — Its Position Is Passive

State Street held a 6.1% stake in ADMA Biologics, which makes plasma-derived medicines for people with weakened immune systems, as of September 30, according to a passive ownership disclosure filed with the SEC Tuesday. The position covered 13,675,348 common shares, which State Street certified it held in the course of ordinary business rather than to influence control of ADMA.

Shared Authority Over The Holding

State Street reported shared disposal authority over all 13,675,348 shares. Its shared voting authority covered 12,892,596 shares; it reported zero shares under sole voting authority.

The 6.1% figure measures State Street's beneficial ownership of ADMA's common-stock class. Its certification places the holding in the passive category, rather than a position acquired or held to change the company's control.

A Rally Already Underway

ADMA shares had gained about 28% over four weeks in coverage published Friday. That gain preceded Tuesday's ownership report; the holding itself was measured as of September 30.

Zacks Equity Research's commentary on Yahoo Finance noted one upward revision to current-year earnings estimates, with no downward revisions. The commentary also described an increase in the consensus earnings estimate.

Plasma Medicines And Collection Centers

ADMA's three FDA-approved products serve patients facing infection risks. ASCENIV and BIVIGAM are intravenous immune globulins used for primary immunodeficiency; Nabi-HB treats acute exposure to hepatitis B.

Physician specialists use the medicines, which reach hospitals, clinics and home infusion providers through national distributors. ADMA BioManufacturing produces them at the company's Boca Raton, Florida plant.

Its Plasma Collection Centers segment supplies plasma for ADMA's medicines and sells remaining plasma to third-party customers. As of December 31, 2025, ADMA operated ten FDA-licensed collection centers in the United States.

Sources

More on ADMA Biologics

All ADMA Biologics (ADMA) coverage →